Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 30;18(2):sfae294.
doi: 10.1093/ckj/sfae294. eCollection 2025 Feb.

Cognitive impairment in CKD patients: a guidance document by the CONNECT network

Collaborators, Affiliations
Review

Cognitive impairment in CKD patients: a guidance document by the CONNECT network

Davide Bolignano et al. Clin Kidney J. .

Abstract

Cognitive impairment is a prevalent and debilitating complication in patients with chronic kidney disease (CKD). This position paper, developed by the Cognitive Decline in Nephro-Neurology: European Cooperative Target network, provides guidance on the epidemiology, risk factors, pathophysiology, diagnosis and clinical management of CKD-related cognitive impairment. Cognitive impairment is significantly more common in CKD patients compared with the general population, particularly those undergoing haemodialysis. The development of cognitive impairment is influenced by a complex interplay of factors, including uraemic neurotoxins, electrolytes and acid-base disorders, anaemia, vascular damage, metabolic disturbances and comorbidities like diabetes and hypertension. Effective screening and diagnostic strategies are essential for early identification of cognitive impairment utilizing cognitive assessment tools, neuroimaging and circulating biomarkers. The impact of various drug classes, including antiplatelet therapy, oral anticoagulants, lipid-lowering treatments and antihypertensive drugs, on cognitive function is evaluated. Management strategies encompass pharmacological and non-pharmacological interventions, with recommendations for optimizing cognitive function while managing CKD-related complications. This guidance highlights the importance of addressing cognitive impairment in CKD patients through early detection, careful medication management and tailored therapeutic strategies to improve patient outcomes.

Keywords: CKD; cognitive impairment; neuroimaging; quality of life; uraemic neurotoxins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest related to this work.

Figures

Figure 1:
Figure 1:
The complex interplay of risk factors contributing to cognitive impairment in CKD patients.
Figure 2:
Figure 2:
The clinical management of cognitive impairment in CKD patients. Key strategies include rehabilitation programs, physical exercise, nutritional optimization and pharmacological management to support cognitive function.

References

    1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 2022;12:7–11. 10.1016/j.kisu.2021.11.003 - DOI - PMC - PubMed
    1. D'Onofrio G, Simeoni M, Rizza Pet al. . Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. Ren Fail 2017;39:45–53. 10.1080/0886022X.2016.1244077 - DOI - PMC - PubMed
    1. Sharma S, Kalra D, Rashid Iet al. . Assessment of health-related quality of life in chronic kidney disease patients: a hospital-based cross-sectional study. Medicina (Lithuania) 2023;59:1788. - PMC - PubMed
    1. Xu H, Garcia-Ptacek S, Trevisan Met al. . Kidney function, kidney function decline, and the risk of dementia in older adults: a registry-based study. Neurology 2021;96:e2956–65. 10.1212/WNL.0000000000012113 - DOI - PMC - PubMed
    1. Tung S, Kendrick J, Surapaneni Aet al. . Association between acute kidney injury and dementia in the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2022;80:495–501. 10.1053/j.ajkd.2022.02.015 - DOI - PMC - PubMed

LinkOut - more resources